Engineered bacteria designed to break down barriers preventing cancer drugs from effectively reaching solid tumors.
neobetherapeutics.comLondonBiotechFounded 2021
8 sources · checked 1 time, last 3h ago
The company's release states US$6.8 million; EU-Startups reports €6.1 million and ECO reports €5.9 million, so the release's figure is used. The release also says a further tranche will fund the first-in-human trial.
2 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The financing also received a non-dilutive grant award from Innovate UK’s Cancer Therapeutics fund; this grant is not counted as round investment.; not on the page it cites, so not applied: date
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | $6.8M $10.5M to date | 2026-11-10 | ARC Ventures | 8 outlets. #25 in Trending |
8 sources · checked 1 time, last 3h ago [ VERIFIED · CORRECTED ] read against 4 of 8 sources
The company's release states US$6.8 million; EU-Startups reports €6.1 million and ECO reports €5.9 million, so the release's figure is used. The release also says a further tranche will fund the first-in-human trial. | ||||
Neobe Therapeutics engineers safe bacteria to enter solid tumors, break down the local barriers that keep immune cells out, and help cancer immunotherapies work for more patients.
Neobe is targeting immune exclusion: fibrotic stroma can keep immune cells and antibodies out of solid tumors, while its engineered bacteria are designed to colonize tumors and express payloads locally to remodel that barrier. The company says it has two proprietary programs with demonstrated preclinical efficacy across colorectal, pancreatic and breast cancer, and its $2.34M 2024 financing was intended to fund preclinical safety and efficacy work and regulatory validation on the path toward clinical development.
Checked against 10 sources today
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $2.3M | 2024-02-29 | not stated | No recent discussion |
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources The financing also received a non-dilutive grant award from Innovate UK’s Cancer Therapeutics fund; this grant is not counted as round investment.; not on the page it cites, so not applied: date [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: neobetherapeutics.com, cancerresearchhorizons.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: Macmillan Cancer Support, Innovate UK, Nadav Rosenberg